Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)
Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)
This is a prospective, non-comparative, interventional, observational pilot study of the
 safety and pharmacokinetics of intravenous (IV) tigecycline in conjunction with standard oral
 therapy in patients with known mild to severe confirmed Clostridium difficile associated
 diarrhea (CDAD).
The intervention is adding Tigecycline (standard doses) to standard oral therapy for CDAD.
 Patients will then be observed for clinical outcomes and relapse of CDAD.
Inclusion Criteria:

 -  non pregnant adults (≥18 years old) with a diagnosis of mild to severe CDAD (initial
 or recurrent) by positive C. difficile toxin assay along with clinical symptoms
 (watery stools, fever, abdominal pain). Patients will receive a minimum of 3 days of
 tigecycline.

 Exclusion Criteria:

 -  pregnant patients

 -  allergy to tetracycline (or tigecycline) antibiotics or patients with life-threatening
 illness.